文献速递淋巴瘤

意大利淋巴瘤基金会MCL0208三期试验中套细胞淋巴瘤的定时与动力学MRD分析

Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma.
PubMed 文献 · Blood · 2022-01-01

该研究基于MCL0208前瞻性三期试验,在300例入组患者中为250例(83%)鉴定出分子标志物,分析234例患者10个时间点的4351项检测结果。ASCT后外周血和骨髓分子缓解率分别为91%和83%,MRD可预测早期进展和长期结局,基于MIPI的动力学模型骨髓AUROC达0.87、外周血达0.81。

要点

  • ASCT诱导高分子缓解率:外周血91%、骨髓83%(RQ-PCR法)。
  • ASCT后6个月MRD预测进展的TTP HR为3.83(P<.001)。
  • 动力学模型联合MIPI的AUROC骨髓达0.87、外周血达0.81。

核心结论

  • MRD是贯穿套细胞淋巴瘤整个自然病程的有力预测指标,适合采用持续调整患者风险的模型。

研究设计与样本

  • 意大利淋巴瘤基金会MCL0208前瞻性三期临床试验,比较ASCT后来那度胺维持治疗与观察。
  • 入组300例患者,250例(83%)鉴定出分子标志物,最终分析234例患者、10个时间点的4351项检测结果。
  • 首次前瞻性综合分析不同技术、分子标志物及组织(外周血和骨髓),在明确时间点采样。

主要发现

  • ASCT诱导高分子缓解率:外周血91%、骨髓83%(RQ-PCR法)。
  • 两臂持续临床和分子缓解的患者数随时间下降,36个月后降至30%。
  • MRD预测早期进展和长期结局,尤其ASCT后6个月:TTP HR为3.83(P<.001)。
  • 单时间点分析中骨髓优于外周血,RQ-PCR更可靠,而巢式PCR适用患者更多(234 vs 176)。
  • 基于定期更新MRD结果和MIPI的时变动力学模型骨髓AUROC达0.87,外周血达0.81,动力学分析后外周血性能与骨髓相当。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Minimal residual disease (MRD) analysis is a known predictive tool in mantle cell lymphoma (MCL). We describe MRD results from the Fondazione Italiana Linfomi phase 3 MCL0208 prospective clinical trial assessing lenalidomide (LEN) maintenance vs observation after autologous stem cell transplantation (ASCT) in the first prospective comprehensive analysis of different techniques, molecular markers, and tissues (peripheral blood [PB] and bone marrow [BM]), taken at well-defined time points. Among the 300 patients enrolled, a molecular marker was identified in 250 (83%), allowing us to analyze 234 patients and 4351 analytical findings from 10 time points. ASCT induced high rates of molecular remission (91% in PB and 83% in BM, by quantitative real-time polymerase chain reaction [RQ-PCR]). Nevertheless, the number of patients with persistent clinical and molecular remission decreased over time in both arms (up to 30% after 36 months). MRD predicted early progression and long-term outcome, particularly from 6 months after ASCT (6-month time to progression [TTP] hazard ratio [HR], 3.83; P < .001). In single-timepoint analysis, BM outperformed PB, and RQ-PCR was more reliable, while nested PCR appeared applicable to a larger number of patients (234 vs 176). To improve MRD performance, we developed a time-varying kinetic model based on regularly updated MRD results and the MIPI (Mantle Cell Lymphoma International Prognostic Index), showing an area under the ROC (Receiver Operating Characteristic) curve (AUROC) of up to 0.87 using BM. Most notably, PB reached an AUROC of up to 0.81; with kinetic analysis, it was comparable to BM in performance. MRD is a powerful predictor over the entire natural history of MCL and is suitable for models with a continuous adaptation of patient risk. The study can be found in EudraCT N. 2009-012807-25 (https://eudract.ema.europa.eu/).

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Ferrero S, Grimaldi D, Genuardi E, et al. Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma. Blood. 2022. PMID: 35737911. doi:10.1182/blood.2021014270

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。